Champions Oncology, Inc. financial data

Symbol
CSBR on Nasdaq
Location
855 N. Wolfe Street, Suite 619, Baltimore, MD
Fiscal year end
April 30
Latest financial report
10-Q - Q2 2025 - Sep 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 90.5 % +40%
Debt-to-equity 784 %
Return On Equity 87.9 % -72.8%
Return On Assets 9.94 %
Operating Margin 4.74 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.8M shares +1.43%
Common Stock, Shares, Outstanding 13.8M shares +1.43%
Entity Public Float 15.4M USD -30%
Common Stock, Value, Issued 14K USD 0%
Weighted Average Number of Shares Outstanding, Basic 13.8M shares +1.43%
Weighted Average Number of Shares Outstanding, Diluted 13.8M shares -1.81%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 56.9M USD +10.1%
Research and Development Expense 7.45M USD -9.17%
Selling and Marketing Expense 7.72M USD +9.56%
General and Administrative Expense 9.38M USD -11.9%
Operating Income (Loss) 2.7M USD -140%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 2.84M USD -134%
Income Tax Expense (Benefit) -82K USD -110%
Net Income (Loss) Attributable to Parent 2.95M USD -133%
Earnings Per Share, Basic 0 USD/shares -130%
Earnings Per Share, Diluted 0 USD/shares -133%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.3M USD +257%
Accounts Receivable, after Allowance for Credit Loss, Current 9.47M USD +4.89%
Assets, Current 21M USD +59.5%
Operating Lease, Right-of-Use Asset 4.77M USD -20%
Goodwill 335K USD 0%
Other Assets, Noncurrent 196K USD +5.95%
Assets 30.5M USD +22.5%
Accounts Payable, Current 4.85M USD -7.45%
Accrued Liabilities, Current 1.8M USD -14.1%
Contract with Customer, Liability, Current 14.4M USD +39.9%
Liabilities, Current 22.7M USD +18.4%
Operating Lease, Liability, Noncurrent 4.24M USD -26%
Other Liabilities, Noncurrent 66K USD -81.8%
Liabilities 27M USD +6.9%
Retained Earnings (Accumulated Deficit) -80.4M USD +3.51%
Stockholders' Equity Attributable to Parent 3.51M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.54M USD
Liabilities and Equity 30.5M USD +22.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 600K USD +92.9%
Net Cash Provided by (Used in) Financing Activities -14K USD +62.2%
Net Cash Provided by (Used in) Investing Activities -46K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 13.9M shares +1.42%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 540K USD +97.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.3M USD +257%
Deferred Tax Assets, Valuation Allowance 14.8M USD -18%
Deferred Tax Assets, Gross 14.8M USD -18%
Operating Lease, Liability 5.75M USD -19.1%
Payments to Acquire Property, Plant, and Equipment 46K USD
Lessee, Operating Lease, Liability, to be Paid 10.4M USD -21.8%
Property, Plant and Equipment, Gross 16.3M USD +0.87%
Operating Lease, Liability, Current 1.51M USD +10%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.87M USD -1.54%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.92M USD -0.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.66M USD -24.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.39M USD -16.6%
Deferred Tax Assets, Operating Loss Carryforwards 8.25M USD -8.74%
Unrecognized Tax Benefits 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.39M USD -16.6%
Depreciation, Depletion and Amortization 1.51M USD -20.7%
Share-based Payment Arrangement, Expense 604K USD -36.6%